Book Review: Biomedical Innovation in Fertility Care – Evidence challenges, commercialisation and the market for hope
By Zeenat Beebeejaun,
PET
| 10. 28. 2024
Building on the 2016 BBC Panorama documentary 'Inside Britain's Fertility Business', which exposed the use of controversial fertility treatment add-ons in private fertility clinics (see BioNews 880), Manuela Perrotta's book, Biomedical Innovation in Fertility Care, unveils regulatory inadequacies that expose patients to abuse by the profit-driven medical industry. Perrotta makes a case for more ethical biomedical innovation in this book and proposes changes that put patients' interests and moral behaviour ahead of business interests.
In doing so, Perrotta explores the commercialisation of reproductive therapies, concentrating on the moral, practical, and legal problems that both experts and patients must deal with. The book criticises the marketing of reproductive treatment add-ons like EmbryoGlue and time-lapse imaging, which are portrayed as potential therapies for supporting pregnancies notwithstanding the lack of solid data proving their efficacy clinics (see BioNews 1240). This system presents serious ethical issues, especially when patients are asked to pay exorbitant costs for experimental procedures.
While reading the book, I found myself reflecting on how Perrotta highlights the restricted role of regulating authorities such as the Competition and...
Related Articles
By Emma McDonald Kennedy
| 09.25.2025
In the leadup to the 2024 election, Donald Trump repeatedly promised to make IVF more accessible. He made the commitment central to his campaign, even referring to himself as the “father of IVF.” In his first month in office, Trump issued an executive order promising to expand IVF access. The order set a 90-day deadline for policy recommendations for “lowering costs and reducing barriers to IVF,” although it didn’t make any substantive reproductive healthcare policy changes.
The response to the...
Sir Francis Galton, 1890s, by Eveleen Myers (née Tennant)
npg.org
Public Domain via Wikipedia
As has been discussed in recent issues of Biopolitical Times (1, 2), there are, increasingly, companies that claim to be selling parents better babies by selecting the “best” embryos. These services don’t come cheap – think $50,000, or even more, for embryo testing, plus perhaps as much again for IVF and concomitant services. To most of us, that is extremely expensive...
By Margaux MacColl, The San Francisco Standard | 09.17.2025
Designer babies are coming soon to an IVF clinic near you.
Nucleus Genomics, founded by Kian Sadeghi in 2020, when he was just 20, got its start analyzing genomes to weigh a person’s risk of everything from cancer to ADHD...
By Marianne Lamers, NEMO Kennislink [cites CGS' Katie Hasson] | 09.23.2025
Een rijtje gespreide vulva’s gaapt de bezoeker aan. Zó ziet een bevalling eruit, en zó een baarmoeder met foetus. Een zwangerschap, maar dan zonder zwangere vrouw, gestript van zorgen, gêne en pijn. De zwangerschapsmodellen en oefenbekkens, te zien in de...